Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer.
Anticancer Res
; 26(4B): 3127-32, 2006.
Article
em En
| MEDLINE
| ID: mdl-16886645
ABSTRACT
BACKGROUND:
The purpose of this cross-sectional study was to evaluate the value of serum tartrate-resistant acid phosphatase 5b (TRACP 5b) and carboxyterminal telopeptide of type I collagen (ICTP) separately and in combination as markers of bone metastases compared to total alkaline phosphatase (tALP) in breast cancer. MATERIALS ANDMETHODS:
Two groups of patients were studied, one with verfied bone metastases (N=46) and one without bone metastases (N=141). Bone marker levels were correlated with the presence or absence of bone metastases.RESULTS:
Serum TRACP 5b concentrations exhibited the largest area under the receiver-operating characteristics (ROC) curve (AUC=0.845), followed by ICTP (0.818) and tALP (0.814) when all patients were included in the analysis. With the combination of TRACP 5b and ICTP, the AUC increased to 0.881. In multivariate regression analysis, all three markers were significant predictors of bone metastases.CONCLUSION:
Serum TRACP 5b, ICTP and tALP exhibited equal performances in the detection of bone metastases. The combination of TRACP with ICTP did not significantly improve the detection of bone metastases over tALP.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Fragmentos de Peptídeos
/
Fosfatase Ácida
/
Neoplasias Ósseas
/
Neoplasias da Mama
/
Biomarcadores Tumorais
/
Pró-Colágeno
/
Isoenzimas
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article